

STN Structure Search (Registry/Caplus)

10/539,539


12/20/2007

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 H, Ak

G2 H, X

G3 H, X, Hy, Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 19:04:10 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 30165 TO ITERATE

6.6% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 592913 TO 613687
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 19:04:15 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED 600961 TO ITERATE

100.0% PROCESSED 600961 ITERATIONS
SEARCH TIME: 00.00.05

L3 90 SEA SSS FUL L1

90 ANSWERS

=> fil caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
172.10	172.31

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 19:04:26 ON 20 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS-1907 - 20 Dec 2007 VOL 147 ISS 26
FILE LAST UPDATED: 19 Dec 2007 (20071219/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13
L4 17 L3

=> d ibib 1

L4 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:1389279 CAPLUS
TITLE: Preparation of benzene compounds having two or more
substituents as liver X receptors (LXR) modulators
INVENTOR(S): Tanaka, Kazuhiko; Yamaguchi, Takahiro; Oda, Kozo;
Terasaka, Tadao; Nakai, Daisuke; Nakadai, Masakazu
PATENT ASSIGNEE(S): Daiichi Sankyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 218pp.
CODEN: JROKAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007314516	A	20071206	JP 2007-107965	20070417
PRIORITY APPLN. INFO.:			JP 2006-121095	A 20060425



L4 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:411602 CAPLUS
DOCUMENT NUMBER: 144:450509
TITLE: Preparation of benzenecarboxylic acid derivatives and
benzenealkanoic acid derivatives as LXR modulators
INVENTOR(S): Tamaki, Kazuhiko; Yamaguchi, Takahiro; Oda, Kozo;
Terasaka, Naoki; Nakai, Daisuke; Nakadai, Masakazu
PATEM ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 353 pp.
DOCUMENT TYPE: CODEN: PIXKD2
Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006046593	A1	20060504	WO 2005-JP19676	20051026
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005297984	A1	20060504	AU 2005-297984	20051026
CA 2585623	A1	20060504	CA 2005-2585623	20051026
JP 2007039425	A	20070215	JP 2005-310867	20051026
EP 1806332	A1	20070711	EP 2005-799391	20051026
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
IN 2007KN01340	A	20070720	IN 2007-KN1340	20070417
NO 2007002690	A	20070727	NO 2007-2690	20070525
PRIORITY APPLN. INFO.:			JP 2004-311821	A 20041027
			JP 2005-187686	A 20050628
			WO 2005-JP19676	W 20051026

OTHER SOURCE(S): MARPAT 144:450509
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L4 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:32063 CAPLUS
 DOCUMENT NUMBER: 144:121798
 TITLE: Tissue factor production inhibitors containing LXR ligands
 INVENTOR(S): Terasaka, Naoki; Hiroshima, Ayano
 PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan
 SOURCE: PCT Int. Appl., 261 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006004030	A1	20060112	WO 2005-JP12185	20050701
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
CA 2572872	A1	20060112	CA 2005-2572872	20050701
EP 1764075	A1	20070321	EP 2005-755860	20050701
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
KR 2007031993	A	20070320	KR 2007-700065	20070102
PRIORITY APPL. INFO.:			JP 2004-196468	A 20040702
			WO 2005-JP12185	W 20050701

OTHER SOURCE(S): MARPAT 144:121798
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT





L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:565185 CAPLUS
 DOCUMENT NUMBER: 141:106267
 TITLE: Preparation of salicylic acid derivatives as ligands of adenine nucleotide translocase
 INVENTOR(S): Ghosh, Soumitra S.; Pei, Yazhong; Tang, Xiao-qing; Litas, Spiros J.; Ahljanian, Michael K.
 PATENT ASSIGNEE(S): Mitokoz, Inc., USA
 SOURCE: PCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
 WO 2004058679 A2 20040715 WO 2003-US41211 20031219
 WO 2004058679 A3 20040826
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW
 RW: BW, GH, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2511178 A1 20040715 CA 2003-2511178 20031219
 AU 2003300358 A1 20040722 AU 2003-300358 20031219
 US 2004192740 A1 20040930 US 2003-741595 20031219
 US 6936638 B2 20050830
 EP 1581472 A2 20051005 EP 2003-814376 20031219
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, EE, HU, SK
 BR 2003017613 A 20051129 BR 2003-17613 20031219
 JP 2006511587 T 20060406 JP 2004-564036 20031219
 US 2006004093 A1 20060105 US 2005-146933 20050607
 MX 2005PA06798 A 20060309 MX 2005-PA6798 20050620
 US 2006194825 A1 20060831 US 2006-539539 20060203
 PRIORITY APPLN. INFO.: US 2002-435420P P 20021220
 US 2003-741595 A1 20031219
 WO 2003-US41211 W 20031219

OTHER SOURCE(S): MARPAT 141:106267
 GI


L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB The title compds. I [R1 = H, halo, NO2, CN, (substituted)alkyl, alkoxy, (substituted)aryl, (substituted)heteroaryl; R2, R3, R5, R6 = H, halo, NO2, CN, (substituted)alkyl, alkoxy, OH, (substituted)aryl, (substituted)heteroaryl; R4 = H, halo, NO2, CN, (substituted)alkyl, (substituted)aryl, (substituted)heteroaryl, (substituted)heteroarylalkyl, etc.; R4 and R5 or R5 and R6, taken together with the carbon atoms to which they are attached, optionally form a (un)substituted homocycle] were prepared for use as ligands of adenine nucleotide translocase in the treatment of conditions associated with altered mitochondrial function.
 For example, compound II was prepared from 3-methylsalicylic acid in a multi-step synthesis. All the compds. in this invention showed satisfied bioactivity in the ANT ligand binding assay.
 IT 721447-07-0P 721447-08-1P 721447-14-9P
 721447-15-0P 721447-17-2P 721447-19-4P
 721447-20-7P 721447-21-8P 721447-22-9P
 721447-23-0P 721447-24-1P 721447-25-2P
 721447-26-3P 721447-27-4P 721447-28-5P
 721447-29-6P 721447-30-9P 721447-31-0P
 721447-32-1P 721447-33-2P 721447-34-3P
 721447-35-4P 721447-36-5P 721447-37-6P

L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

721447-38-7P 721447-39-8P 721447-40-1P
 721447-41-2P 721447-42-3P 721447-43-4P
 721447-44-5P 721447-45-6P 721447-46-7P
 721447-47-8P 721447-48-9P 721447-49-0P
 721447-50-3P 721447-51-4P 721447-52-5P
 721447-53-6P 721447-54-7P 721447-55-8P
 721447-56-9P 721447-57-0P 721447-58-1P
 721447-59-2P 721447-60-5P 721447-61-6P
 721447-62-7P 721447-63-8P 721447-64-9P
 721447-65-0P 721447-66-1P 721447-67-2P
 721447-68-3P 721447-69-4P 721447-70-7P
 721447-71-8P 721447-72-9P 721447-73-0P
 721447-74-1P 721447-75-2P 721447-76-3P
 721447-77-4P 721447-78-5P 721447-79-6P
 721447-80-9P 721447-81-0P 721447-82-1P
 721447-83-2P 721448-54-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Prepn. of salicylic acid derivs. as ligands of adenine nucleotide translocase)
 RN 721447-07-0 CAPLUS
 CN Benzoic acid, 2-hydroxy-3-[(4-pentylphenoxy)methyl]- (CA INDEX NAME)




RN 721447-08-1 CAPLUS
 CN Benzoic acid, 3-[(3-bromophenoxy)methyl]-2-hydroxy-5-methyl- (CA INDEX NAME)




RN 721447-14-9 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 5-[[4-(1,1-dimethylethyl)phenoxy]methyl]-4-hydroxy-4'-methoxy- (CA INDEX NAME)


L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 721447-15-0 CAPLUS
 CN Benzoic acid, 5-bromo-3-[[4-(1,1-dimethylethyl)phenoxy]methyl]-2-hydroxy- (CA INDEX NAME)



RN 721447-17-2 CAPLUS
 CN Benzoic acid, 2-hydroxy-5-methyl-3-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yloxy]methyl]- (CA INDEX NAME)




RN 721447-19-4 CAPLUS
 CN Benzoic acid, 3-[[2,6-bis(1,1-dimethylethyl)phenoxy]methyl]-2-hydroxy-5-methyl- (CA INDEX NAME)




RN 721447-20-7 CAPLUS
 CN Benzoic acid, 3-[[4-benzoylphenoxy]methyl]-2-hydroxy-5-methyl- (CA INDEX NAME)


L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 721447-21-8 CAPLUS
CN Benzoic acid,
3-[(4-(1,1-dimethylethyl)phenoxy)methyl]-2-hydroxy-5-methyl-
(CA INDEX NAME)




RN 721447-22-9 CAPLUS
CN Benzoic acid, 3-[(4-chlorophenoxy)methyl]-2-hydroxy-5-methyl- (CA INDEX NAME)




RN 721447-23-0 CAPLUS
CN Benzoic acid, 3-[(2,3-dichlorophenoxy)methyl]-2-hydroxy-5-methyl- (CA INDEX NAME)


L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 721447-24-1 CAPLUS
CN Benzoic acid, 2-hydroxy-5-methyl-3-[(4-(phenylmethoxy)phenoxy)methyl]-
(CA INDEX NAME)




RN 721447-25-2 CAPLUS
CN Benzoic acid,
3-[(4-(1,1-dimethylpropyl)phenoxy)methyl]-2-hydroxy-5-methyl-
(CA INDEX NAME)




RN 721447-26-3 CAPLUS
CN Benzoic acid, 3-[(1,1'-biphenyl)-4-yloxy)methyl]-2-hydroxy-5-methyl-
(CA INDEX NAME)


L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 721447-27-4 CAPLUS
CN Benzoic acid, 3-[(3-chlorophenoxy)methyl]-2-hydroxy-5-methyl- (CA INDEX NAME)



RN 721447-28-5 CAPLUS
CN Benzoic acid,
2-hydroxy-3-[(4'-methoxy(1,1'-biphenyl)-4-yloxy)methyl]-5-methyl-
(CA INDEX NAME)




RN 721447-29-6 CAPLUS
CN Benzoic acid,
3-[(1,1-dimethylethyl)phenoxy)methyl]-2-hydroxy-5-methyl-
(CA INDEX NAME)




RN 721447-30-9 CAPLUS
CN Benzoic acid, 3-[(1,1'-biphenyl)-2-yloxy)methyl]-2-hydroxy-5-methyl-
(CA INDEX NAME)


L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 721447-31-0 CAPLUS
CN Benzoic acid, 2-hydroxy-5-methyl-3-[(1,1,3,3-tetramethylbutyl)phenoxy)methyl]-
(CA INDEX NAME)



RN 721447-32-1 CAPLUS
CN Benzoic acid, 2-hydroxy-3-(phenoxymethyl)-5-(1,1,3,3-tetramethylbutyl)-
(CA INDEX NAME)




RN 721447-33-2 CAPLUS
CN Benzoic acid, 3-[(4-bromophenoxy)methyl]-2-hydroxy-5-(1,1,3,3-tetramethylbutyl)-
(CA INDEX NAME)




L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 721447-34-3 CAPLUS
 CN Benzoic acid, 3-[(2-ethoxyphenoxy)methyl]-2-hydroxy-5-(1,1,3,3-tetramethylbutyl)- (CA INDEX NAME)



RN 721447-35-4 CAPLUS
 CN Benzoic acid, 3-[[[2,3-dihydro-1H-inden-5-yl]oxy]methyl]-2-hydroxy-5-methyl- (CA INDEX NAME)




RN 721447-36-5 CAPLUS
 CN Benzoic acid, 3-[[5-[(3-carboxy-2-hydroxy-5-methylphenyl)methoxyl]-2,3-dihydro-1H-inden-4-yl]methyl]-2-hydroxy-4-methyl-, 1-methyl ester (CA INDEX NAME)




RN 721447-37-6 CAPLUS
 CN Benzoic acid, 3-[[2,6-bis(1,1-dimethylethyl)-4-methylphenoxy]methyl]-2-

L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


hydroxy-5-methyl- (CA INDEX NAME)



RN 721447-38-7 CAPLUS
 CN Benzoic acid, 2-hydroxy-5-methyl-3-[(4-methylphenoxy)methyl]- (CA INDEX NAME)




RN 721447-39-8 CAPLUS
 CN Benzoic acid, 2-hydroxy-3-[[4-(methoxycarbonyl)phenoxy]methyl]-5-(1,1,3,3-tetramethylbutyl)- (CA INDEX NAME)




RN 721447-40-1 CAPLUS
 CN Benzoic acid, 3-[[4-(aminocarbonyl)-2,6-dimethoxyphenoxy]methyl]-2-hydroxy-5-(1,1,3,3-tetramethylbutyl)- (CA INDEX NAME)


L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 721447-41-2 CAPLUS
 CN Benzoic acid, 2-hydroxy-3-[[2-(hydroxymethyl)phenoxy]methyl]-5-(1,1,3,3-tetramethylbutyl)- (CA INDEX NAME)




RN 721447-42-3 CAPLUS
 CN Benzoic acid, 3-[[2-(2-benzothiazolyl)phenoxy]methyl]-2-hydroxy-5-(1,1,3,3-tetramethylbutyl)- (CA INDEX NAME)




RN 721447-43-4 CAPLUS
 CN Benzoic acid, 3,3'-[[2,5-bis(1,1-dimethylethyl)-1,4-phenylene]bis(oxyethylene)]bis[2-hydroxy-5-methyl- (CA INDEX NAME)


L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 721447-44-5 CAPLUS
 CN Benzoic acid, 3-[[2-(1,1-dimethylethyl)phenoxy]methyl]-2-hydroxy-5-methyl- (CA INDEX NAME)



RN 721447-45-6 CAPLUS
 CN Benzoic acid, 3-[[2-(2-benzothiazolyl)phenoxy]methyl]-2-hydroxy- (CA INDEX NAME)




RN 721447-46-7 CAPLUS
 CN Benzoic acid, 3-[[4-(1,1-dimethylpropyl)phenoxy]methyl]-2-hydroxy- (CA INDEX NAME)




L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 721447-47-8 CAPLUS
 CN Benzoic acid, 3-[(4-bromophenoxy)methyl]-2-hydroxy-5-methyl- (CA INDEX NAME)



RN 721447-48-9 CAPLUS
 CN Benzoic acid, 3-[(4-chloro-2-methylphenoxy)methyl]-2-hydroxy-5-methyl- (CA INDEX NAME)




RN 721447-49-0 CAPLUS
 CN Benzoic acid, 3-[[4'-bromo[1,1'-biphenyl]-4-yl]oxy]methyl]-2-hydroxy-5-methyl- (CA INDEX NAME)




RN 721447-50-3 CAPLUS
 CN Benzoic acid, 2-hydroxy-3-[(4-iodophenoxy)methyl]-5-methyl- (CA INDEX NAME)

L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 721447-54-7 CAPLUS
 CN Benzoic acid, 3-[(2,3-dihydro-1H-inden-4-yl)oxy]methyl]-2-hydroxy-5-methyl- (CA INDEX NAME)



RN 721447-55-8 CAPLUS
 CN Benzoic acid, 2-hydroxy-3-[(2-iodophenoxy)methyl]-5-methyl- (CA INDEX NAME)




RN 721447-56-9 CAPLUS
 CN Benzoic acid, 3-[(2-fluoro-5-methylphenoxy)methyl]-2-hydroxy-5-methyl- (CA INDEX NAME)




RN 721447-57-0 CAPLUS
 CN Benzoic acid, 3-[(2,4-dichlorophenoxy)methyl]-2-hydroxy-5-methyl- (CA INDEX NAME)


L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 721447-51-4 CAPLUS
 CN Benzoic acid, 2-hydroxy-3-[(3-iodophenoxy)methyl]-5-methyl- (CA INDEX NAME)



RN 721447-52-5 CAPLUS
 CN Benzoic acid, 3-[(4-ethylphenoxy)methyl]-2-hydroxy-5-methyl- (CA INDEX NAME)




RN 721447-53-6 CAPLUS
 CN Benzoic acid, 2-hydroxy-5-methyl-3-[(2,3,5-trimethylphenoxy)methyl]- (CA INDEX NAME)




L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 721447-58-1 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-acetyl-5-[[4-(1,1-dimethylethyl)phenoxy]methyl]-4-hydroxy- (CA INDEX NAME)



RN 721447-59-2 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 5-[[4-(1,1-dimethylethyl)phenoxy]methyl]-4'-fluoro-4-hydroxy- (CA INDEX NAME)




RN 721447-60-5 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 5-[[4-(1,1-dimethylethyl)phenoxy]methyl]-4'-hydroxy-4'-(trifluoromethyl)- (CA INDEX NAME)




RN 721447-61-6 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-chloro-5-[[4-(1,1-


L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
dimethylethyl)phenoxy)methyl]-4'-fluoro-4-hydroxy- (CA INDEX NAME)



RN 721447-62-7 CAPLUS
CN Benzoic acid,
5-((2-benzofuranyl)-3-[[4-(1,1-dimethylethyl)phenoxy)methyl]-
2-hydroxy- (CA INDEX NAME)




RN 721447-63-8 CAPLUS
CN Benzoic acid, 5-benzo(b)thien-2-yl-3-[[4-(1,1-
dimethylethyl)phenoxy)methyl]-2-hydroxy- (CA INDEX NAME)




RN 721447-64-9 CAPLUS
CN (1,1'-Biphenyl)-3-carboxylic acid, 5-[[4-(1,1-
dimethylethyl)phenoxy)methyl]-3',5'-difluoro-4-hydroxy- (CA INDEX NAME)


L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 721447-65-0 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 5-[[4-(1,1-
dimethylethyl)phenoxy)methyl]-4-hydroxy-3'-(trifluoromethyl)- (CA INDEX NAME)




RN 721447-66-1 CAPLUS
CN Benzoic acid, 3-[[4-(1,1-dimethylethyl)phenoxy)methyl]-2-hydroxy-5-(3-
thienyl)- (CA INDEX NAME)




RN 721447-67-2 CAPLUS
CN Benzoic acid, 3-[[4-(1,1-dimethylethyl)phenoxy)methyl]-2-hydroxy-5-(2-
thienyl)- (CA INDEX NAME)


L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 721447-68-3 CAPLUS
CN Benzoic acid, 2-hydroxy-5-methyl-3-[[3-(2-thienyl)phenoxy)methyl]- (CA INDEX NAME)



RN 721447-69-4 CAPLUS
CN Benzoic acid,
2-hydroxy-3-[[4-(4'-methoxy[1,1'-biphenyl]-3-yl)oxy)methyl]-5-
methyl- (CA INDEX NAME)




RN 721447-70-7 CAPLUS
CN Benzoic acid, 3-[[3-(2-benzofuranyl)phenoxy)methyl]-2-hydroxy-5-methyl-
(CA INDEX NAME)




RN 721447-71-8 CAPLUS
CN Benzoic acid, 3-[[3-(2-benzofuranyl)phenoxy)methyl]-2-hydroxy-5-methyl-
(CA INDEX NAME)


L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 721447-72-9 CAPLUS
CN Benzoic acid, 2-hydroxy-5-methyl-3-[[4-(2-thienyl)phenoxy)methyl]- (CA INDEX NAME)



RN 721447-73-0 CAPLUS
CN Benzoic acid, 3-[[4-(2-benzofuranyl)phenoxy)methyl]-2-hydroxy-5-methyl-
(CA INDEX NAME)




RN 721447-74-1 CAPLUS
CN Benzoic acid, 3-[[2'-(2-benzofuranyl)phenoxy)methyl]-2-hydroxy-5-methyl-
(CA INDEX NAME)




RN 721447-75-2 CAPLUS
CN Benzoic acid, 3-[[3',5'-bis(trifluoromethyl)(1,1'-biphenyl)-3-
yl]oxy)methyl]-2-hydroxy-5-methyl- (CA INDEX NAME)


L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 721447-76-3 CAPLUS
CN Benzoic acid, 2-hydroxy-5-methyl-3-[[[3'-nitro[1,1'-biphenyl]-3-yl]oxy]methyl]- (CA INDEX NAME)



RN 721447-77-4 CAPLUS
CN Benzoic acid, 2-hydroxy-5-methyl-3-[[[4'-(1-methylethyl)[1,1'-biphenyl]-3-yl]oxy]methyl]- (CA INDEX NAME)




RN 721447-78-5 CAPLUS
CN Benzoic acid, 3-[[[3-(2-furanyl)phenoxy]methyl]-2-hydroxy-5-methyl]- (CA INDEX NAME)




RN 721447-79-6 CAPLUS
CN Benzoic acid, 2-hydroxy-5-methyl-3-[[[4'-(1-methylethyl)[1,1'-biphenyl]-4-yl]oxy]methyl]- (CA INDEX NAME)

L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 721447-83-2 CAPLUS
CN Benzoic acid, 3-[[[4-(1,1-dimethylethyl)-2-hydroxyphenoxy]methyl]-2-hydroxy-5-methyl]- (CA INDEX NAME)




RN 721448-54-0 CAPLUS
CN Benzoic acid, 2-hydroxy-5-methyl-3-[[[4-(1,1-dimethylethyl)-2-hydroxyphenoxy]methyl]-2-hydroxy-5-methyl]- (CA INDEX NAME)




L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


yl]oxy]methyl)- (CA INDEX NAME)




RN 721447-80-9 CAPLUS
CN Benzoic acid, 2-hydroxy-5-methyl-3-[(2,4,5-trichlorophenoxy)methyl]- (CA INDEX NAME)



RN 721447-81-0 CAPLUS
CN Benzoic acid, 2-hydroxy-5-methyl-3-[(3-(trifluoromethyl)phenoxy)methyl]- (CA INDEX NAME)



RN 721447-82-1 CAPLUS
CN Benzoic acid, 3-[[[4-(1,1-dimethylethyl)phenoxy]methyl]-2-hydroxy-5-methyl]- (CA INDEX NAME)




L4 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:412769 CAPLUS
DOCUMENT NUMBER: 140:423576
TITLE: Preparation of benzofuran compounds for treatment and prophylaxis of hepatitis C viral infections and associated diseases
INVENTOR(S): Burns, Christopher J.; Del Vecchio, Alfred M.; Bailey,
Thomas R.; Kulkarni, Bheemashankar A.; Faltg, Thomas H.; Sher, Susan R.; Blackledge, Charles W.; Rys, David J.; Lessen, Thomas A.; Swestock, John; Deng, Yijun; Nitz, Theodore J.; Reinhardt, Jason A.; Feng, Hao; Saha, Ashis K.
PATENT ASSIGNEE(S): Viropharma Incorporated, USA; Wyeth, John, and Brother
SOURCE: PCT Int. Appl., 299 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041201	A2	20040521	WO 2003-US34962	20031031
WO 2004041201	A3	20040819		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2504344	A1	20040521	CA 2003-2504344	20031031
AU 2003290584	A1	20040607	AU 2003-290584	20031031
US 2004162318	A1	20040819	US 2003-699336	20031031
US 7265152	B2	20070904		
BR 2003015937	A	20050913	BR 2003-15937	20031031
EP 1581207	A2	20051005	EP 2003-783119	20031031
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1731993	A	20060208	CN 2003-80107884	20031031
JP 2006510736	T	20060330	JP 2005-502256	20031031
NO 2005002071	A	20050523	NO 2005-2071	20050427
MX 2005PA04608	A	20050920	MX 2005-PA4608	20050429
IN 2005DN02291	A	20070119	IN 2005-DN2291	20050530
US 2007231318	A1	20071004	US 2007-753145	20070524
PRIORITY APPLN. INFO.:			US 2002-423291P	P 20021101
			US 2003-461077P	P 20030408
			US 2003-489060P	P 20030721
			US 2003-515944P	P 20031030

L4 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 US 2003-699336 A1 20031031
 WO 2003-US4962 W 20031031

OTHER SOURCE(S): MARPAT 140:423576
 GI



AB The title compds. [I; R1 = H, alkyl, halo, CN; R2 = H, alkyl, alkoxy, OH, etc.; R3 = H, alkyl, alkoxy, alkenyl, etc.; R4 = H, alkyl, halo, alkoxy; R5 = alkyl, cycloalkyl, cycloalkylalkyl; R6 = aryl, heteroaryl], useful for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the hepatitis C virus, were prepared E.g., a 4-step synthesis of 2-(furan-3-yl)-5-methoxybenzofurancarboxylic acid methylamide (starting from Et β-oxo-3-furanpropionate and 1,4-benzoquinone) which showed IC50 of 0.5 to 55.0 μM against HCV polymerase (BB7), was given. The pharmaceutical composition comprising the compound I is claimed.

IT 691852-54-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzofuran-3-carboxamides for treatment and prophylaxis of hepatitis C viral infections and associated diseases)

RN 691852-54-7 CAPLUS
 CN Benzoic acid, 4-[[[2-(4-fluorophenyl)-3-[(methylamino)carbonyl]-6-methyl(methylsulfonyl)amino]-5-benzofuranyl]oxy]methyl]-2-hydroxy- (CA INDEX NAME)

L4 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 2003:491149 CAPLUS

DOCUMENT NUMBER: 139:69524

TITLE: Preparation of small-molecule inhibitors of interleukin-2

INVENTOR(S): Arkin, Michelle R.; McDowell, Robert S.; Oslob, Johan D.; Palamido, Brian C.; Waal, Nathan D.; Yu, Chul

Hyun

PATENT ASSIGNEE(S): Sunesis Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051797	A2	20030626	WO 2002-US40430	20021217
WO 2003051797	A3	20040115		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003149049	A1	20030807	US 2001-24665	20011217
US 6806279	B2	20041019		
AU 2002357882	A1	20030630	AU 2002-357882	20021217
			US 2001-24665	A 20011217
PRIORITY APPLN. INFO.:			WO 2002-US40430	W 20021217

OTHER SOURCE(S): MARPAT 139:69524
 GI

L4 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L4 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The invention describes compds. I [B = CH2CH2, CH2CH2NH, CH2OCH2, CONH, CO, SO, SO2NH, etc.; J = absent, S, CH2O, NH, CO, etc.; B = amino, amidino, (un)substituted Ph, naphthyl, cycloalkyl, heterocyclyl, etc.; A = N or CH; X = null, CH2 or CH2CH2, which may be substituted; Y = null or CH2; R = (un)substituted Ph, pyridyl, cyclopentadienyl, pyrrolyl, furyl, or thienyl; R1 = H, alkyl, haloalkyl, cycloalkyl; R2 = H and R3 = H, (cyclo)alkyl, halo, alkoxy, etc. or CR2R3 = CO; R4 = H, OH, alkoxy, (cyclo)alkyl, halo, haloalkyl, and amino acid derivs. II [same B, J, and M; R5 = (un)substituted phenyl; R6, R7 = H, CN, NO2, Ph, PhO, PhCH2, (cyclo)alkyl, etc.; R8 = H, (cyclo)alkyl, aryl, acetylaminoalkyl, etc.] which IL-2/IL-2R binding and are useful for the treatment of interleukin-2 mediated diseases, such as autoimmune diseases (such as rheumatoid arthritis, multiple sclerosis, uveitis, and psoriasis), allograft rejection, and graft-vs.-host disease. Thus, H2NC(:NH)-D-Ala-Gly-(4-PhC.tplbond.C-l-Phe)-OMe was prepared coupling/deprotection reactions of 4-phenylethynyl-substituted phenylalanine Me ester hydrochloride with Boc-glycine (Boc = tert-butoxycarbonyl), Boc-D-alanine, and 1-pyrazolyl-C(:NBoc)NHBOC.


IT 550377-87-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of small-mol. inhibitors of interleukin-2)

RN 550377-87-2 CAPLUS
 CN Benzoic acid, 4-[[[4-[5-[1-[[[(2R)-2-[(aminoimino)methyl]amino]-4-methyl-1-oxopentyl]amino]acetyl]-4-piperidinyl]-1-methyl-1H-pyrazol-3-yl]-2,3-dichlorophenoxy]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN. (Continued)



PAGE 1-B

CO₂H

L4 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:396829 CAPLUS

DOCUMENT NUMBER: 138:401499

TITLE: Preparation of benzophenone derivatives as AP-1 inhibitors for treatment of arthritis

INVENTOR(S): Hirono, Shuichi; Shiozawa, Shunichi; Chaki, Hisaaki

Kotabe, Hironori; Tanaka, Tadashi; Aikawa, Yukihiko

PATENT ASSIGNEE(S): Toyama Chemical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 258 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003042150	A1	20030522	WO 2002-JP11846	20021113
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MO, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SE, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2467261	A1	20030522	CA 2002-2467261	20021113
AU 2002349777	A1	20030526	AU 2002-349777	20021113
EP 1445249	A1	20040811	EP 2002-781763	20021113
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TH, BG, CZ, EE, SK			
BR 2002014177	A	20040914	BR 2002-14177	20021113
HU 2004002025	A2	20050228	HU 2004-2025	20021113
NZ 532810	A	20050324	NZ 2002-532810	20021113
CN 1602291	A	20050330	CN 2002-824812	20021113
ZA 2004003373	A	20051118	ZA 2004-3373	20021113
CN 101054345	A	20071017	CN 2007-10101148	20021113
IN 2004KN00591	A	20060421	IN 2004-KN591	20040505
MX 2004PA04654	A	20050517	MX 2004-PA4654	20040514
NO 2004002495	A	20040811	NO 2004-2495	20040615
US 2005113400	A1	20050526	US 2004-493223	20041215
PRIORITY APPL. INFO.:			JP 2001-351217	A 20011116
			JP 2002-209382	A 20020718
			CN 2002-824812	A3 20021113
			WO 2002-JP11846	W 20021113

OTHER SOURCE(S): MARPAT 138:401499
GI

L4 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN. (Continued)



AB The title compds. I [wherein R1 = (un)substituted heterocyclyl, Ph, or alkyl; Z = (un)substituted alkylene; R2 = (un)substituted heterocyclyl(carbonyl) or CO₂H; R3 = H, halo, CN, NO₂, SH, carbamoyl, (un)substituted CO₂H, OH, NH₂, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, alkoxy, aryloxy, acyl, alkoxy-CO, aryloxy-CO, alkylthio, alkyl-SO, alkyl-SO₂, alkylamino, acylamino, alkyl-SO₂-amino, aryl-SO₂-amino, or heterocyclyl; R4 = (un)substituted alkoxy, cycloalkyloxy, cycloalkenyloxy, alkyl, cycloalkyl, or heterocyclyl(oxy); R5 = H, halo, or OH; with proviso] and salts thereof are prepared as AP-1 inhibitors for the treatment of autoimmune diseases and chronic articular rheumatism. For example, the benzophenone derivative II was prepared in a multi-step synthesis.

II showed IC₅₀ of 110 μM against AP-1.

IT 530141-70-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(AP-1 inhibitor; preparation of benzophenone deriva. as AP-1 inhibitors for

treatment of arthritis)

RN 530141-70-9 CAPLUS

CN Benzenepropanoic acid, 2-[(4-carboxy-2-hydroxyphenyl)methoxy]-5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]- (CA INDEX NAME)



L4 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN. (Continued)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

DOCUMENT NUMBER:

TITLE:

INVENTOR(S):
Russell

Havran,

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:


FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6214877	B1	20010410	US 1999-307850	19990510
US 2001018525	A1	20010830	US 2001-771469	20010126
US 6451827	B2	20020917		
US 2003083341	A1	20030501	US 2002-215438	20020809
US 6765021	B2	20040720		
US 2004214869	A1	20041028	US 2004-843026	20040511
US 7008636	B2	20060307		
PRIORITY APPLN. INFO.:				
			US 1998-108154P	P 19980512
			US 1999-307850	A3 19990510
			US 2001-771469	A3 20010126
			US 2002-215438	A3 20020809

OTHER SOURCE(S):
GI

MARPAT 134:280608



L4 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 112 THERE ARE 112 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB RIOZR [I: R = OH, alkyl, alkoxy, (hetero)aryl(alkyl), ureido, etc.; R1 = H, (carboxy)alkyl, etc.; Z = (un)substituted 2-aryl-1,4-phenylene] were prepared. Thus, 4-(HO)C6H4CO2Et was brominated and the iodinated product etherified by HOCH2CH2OH to give Et 3-bromo-4-(2-hydroxyethoxy)-5-iodobenzoate which was arylated by 3-ClC6H4B(OH)2 and the product amidated by dodecylamine to give, after saponification, title compound II [R = Bu(CH2)8NHCO].


IT Data for biol. activity of I were given.

IT 251476-96-7P 251477-04-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of bi- and terphenylcarboxamides as protein tyrosine phosphatase inhibitors)

RN 251476-96-7 CAPLUS

CN Benzoic acid, 2-hydroxy-4-[[[5'-[[[8-phenyloctyl]amino]carbonyl]-3,3'-bis(trifluoromethyl)]1,1':3',1''-terphenyl]-2'-yl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 251477-04-0 CAPLUS

CN Benzoic acid, 4-[[[3-bromo-5-[[[8-phenyloctyl]amino]carbonyl]-3'-[[trifluoromethyl]]1,1'-biphenyl]-2-yl]oxy]methyl]-2-hydroxy- (CA INDEX NAME)

L4 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

DOCUMENT NUMBER:

TITLE:

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:


FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6063815	A	20000516	US 1999-307920	19990510
PRIORITY APPLN. INFO.:				
			US 1998-100427P	P 19980512

OTHER SOURCE(S):
GI

MARPAT 132:334280



AB YXZCOR [I: R = (un)substituted Ph; X = O, NR6, CH2NR6; R6 = H or alkyl; Y = SO2R1, CH2R1, CH2CO2R7; R1 = (un)substituted (hetero)aryl; R7 = H or alkyl; Z = 2,6-(un)substituted 1,4-phenylene] were prepared for treatment of insulin resistance and hyperglycemia. Thus, 4-(HO)C6H4COPh was bisiodinated and the O-protected product condensed with PhB(OH)2 to give, after deprotection, [2'-hydroxy[[1,1':3',1''terphenyl]-5'-yl]phenylmethanone which was O-acylated by 2,4-(HO)(ClO2S)C6H3CO2H to give title compound II. Data for biol. activity of I were given.


IT 267883-84-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 4-aryloxysulfonyl-2-hydroxybenzoates and analogs as insulin receptor protein tyrosine phosphatase 1B inhibitors)

RN 267883-84-1 CAPLUS

CN Benzoic acid, 4-[[[5'-benzoyl[[1,1':3',1''-terphenyl]-2'-yl]oxy]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:764010 CAPLUS

DOCUMENT NUMBER: 132:12200

TITLE: Preparation of terphenyloxyalkanoic acids and analogs as protein-tyrosine phosphatase inhibitors

INVENTOR(S):

Butera, John Anthony; Caulfield, Craig Eugene; Graceffa, Russell Francis; Greenfield, Alexander; Gundersen, Eric Gould; Havran, Lisa Marie; Katz, Alan Howard; Lennox, Joseph Richard; Mayer, Scott Christian; McDevitt, Robert Emmett

PATENT ASSIGNEE(S):

American Home Products Corporation, USA

SOURCE:

PCT Int. Appl., 277 pp.

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9961410	A1	19991202	WO 1999-US10158	19990510
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MM, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MM, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2331056	A1	19991202	CA 1999-2331056	19990510
AU 9940727	A	19991213	AU 1999-40727	19990510
EP 1077929	A1	20010228	EP 1999-924158	19990510
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2002516305	T	20020604	JP 2000-550819	19990510
MX 2000PA11094	A	20010405	MX 2000-PA11094	20001110
PRIORITY APPLN. INFO.:				
			US 1998-76709	A 19980512
			WO 1999-US10158	W 19990510

OTHER SOURCE(S):

MARPAT 132:12200

GI



AB Title compds. [I; R = H, alkyl, SO2ZCO2H, CH2CO2H, (hetero)arylmethyl,

L4 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

etc.; R1, R2 = H, halo, alkyl, (hetero)aryl, etc.; R3 = alkyl, (hetero)aryl(alkyl), alkoxy(methyl), (un)substituted CONH2, etc.; Z = hydroxyphenyl were prep'd. Thus, Et 2-bromo-4-(2-hydroxyethoxy)-5-iodobenzoate was condensed with 3-ClC6H4B(OH)2 and the product amidated

by dodecylamine to give, after oxidn., I (R = CH2CO2H, R1 = R2 = C6H4Cl-3,

R3 = dodecylcarbamoyl). Data for biol. activity of I were given.

IT 251476-96-7P 251477-04-0P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted biphenyl-, aryl, and terphenyloxyalkanoic

acids as inhibitors for protein-tyrosine phosphatases in treatment of


insulin resistance and hyperglycemia)

RN 251476-96-7 CAPLUS

CN Benzoic acid, 4-[[[3-bromo-5-[[[8-phenyloctyl]amino]carbonyl]-3,3'-

bis(trifluoromethyl)[1,1':3',1''-terphenyl]-2-yl]oxy)methyl]-2-hydroxy-

(CA INDEX NAME)




RN 251477-04-0 CAPLUS

CN Benzoic acid, 4-[[[3-bromo-5-[[[8-phenyloctyl]amino]carbonyl]-3,3'-bis(trifluoromethyl)[1,1':3',1''-terphenyl]-2-yl]oxy)methyl]-2-hydroxy-

(CA INDEX NAME)

L4 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT:

26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR

THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT


L4 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1998:424220 CAPLUS
 DOCUMENT NUMBER: 129:95327
 TITLE: Preparation of sulfonamide and carboxamide derivatives

INVENTOR(S): as drugs
 Ohuchida, Shuichi; Nagao, Yuuki
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan; Ohuchida, Shuichi; Nagao, Yuuki
 SOURCE: PCT Int. Appl., 305 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9827053	A1	19980625	WO 1997-JP4593	19971212
W: AU, CA, CN, HU, JP, KR, MX, NO, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
TW 523506	B	20030311	TW 1997-86118583	19971210
CA 2274954	A1	19980625	CA 1997-2274954	19971212
AU 9854115	A	19980715	AU 1998-54115	19971212
AU 733493	B2	20010517		
EP 947500	A1	19991006	EP 1997-947925	19971212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1247529	A	20000315	CN 1997-181861	19971212
HU 2000001536	A2	20000928	HU 2000-1536	19971212
HU 2000001536	A3	20010228		
JP 3426252	B2	20030714	JP 1998-527533	19971212
ZA 9711336	A	19980625	ZA 1997-11336	19971217
KR 2000057576	A	20000925	KR 1999-705335	19990615
NO 9902935	A	19990816	NO 1999-2935	19990616
MX 9905770	A	20000228	MX 1999-5770	19990618
US 6448290	B1	20020910	US 1999-331327	19990618
US 2003060460	A1	20030327	US 2002-207078	20020730
US 6790866	B2	20040914		
PRIORITY APPL. INFO.:			JP 1996-353818	A 19961218
			JP 1997-305055	A 19971021
			WO 1997-JP4593	W 19971212
			US 1999-331327	A3 19990618

OTHER SOURCE(S): MARPAT 129:95327
 GI For diagram(s), see printed CA Issue.
 AB The title compds. (I: rings A and B represent each a carbocycle or a heterocycle; Z1 represents COR1, CH-CHCOR1, etc.; R1 represents OH, Cl-4 alkoxy, etc.; Z2 represents H, alkyl, etc.; Z3 represents a single bond or alkylene; Z4 represents SO2 or CO; Z5 represents alkyl, Ph, a heterocycle,

L4 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE


FORMAT

L4 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 etc., R2 represents CONR8, O, S, etc.; R8 represents H, Cl-4 alkyl; R3 represents H, alkyl, halo, CF3, etc.; R4 represents H, optionally substituted alkyl, etc.; n, t = 1-4 are prepd. I bind to prostaglandin E2 (PGE2) receptors and exert an antagonism. I have the effects of inhibiting uterine muscle contraction, analgesia, inhibiting digestive tract movement, hypnosis, enlarging vesical capacity, contracting the uterine, promoting the digestive tract movement, suppressing the secretion of gastric hydrochloric acid, lowering blood pressure, or diuresis.

Thus, compd. (II; W = Me) was treated with aq. NaOH and followed by aq. HCl to give the title compd. II (W = H), which showed Ki of 0.099 μM against PGE2 receptors.
 IT 209687-48-9P 209687-49-0P 209687-50-3P
 AL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (Preparation of sulfonamide and carboxamide derivs. as drugs)
 RN 209687-48-9 CAPLUS
 CN Benzoic acid, 2-hydroxy-4-[[2-[(phenylsulfonyl)propylamino]-5-(trifluoromethyl)phenoxy]methyl]- (CA INDEX NAME)



RN 209687-49-0 CAPLUS
 CN Benzoic acid, 2-hydroxy-4-[[5-methyl-2-[(phenylsulfonyl)propylamino]phenoxy]methyl]- (CA INDEX NAME)




RN 209687-50-3 CAPLUS
 CN Benzoic acid, 4-[[5-chloro-2-[(phenylsulfonyl)propylamino]phenoxy]methyl]-2-hydroxy- (CA INDEX NAME)

L4 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1996:425268 CAPLUS
 DOCUMENT NUMBER: 125:86305
 TITLE: Ortho-substituted aromatic ether compounds and their use in pharmaceutical compositions for pain relief
 INVENTOR(S): Breaault, Gloria Anne; Oldfield, John; Tucker, Howard; Warner, Peter
 PATENT ASSIGNEE(S): Zeneca Limited, UK
 SOURCE: PCT Int. Appl., 146 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9606822	A1	19960307	WO 1995-GB2030	19950829
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9533519	A	19960322	AU 1995-33519	19950829
EP 778821	A1	19970618	EP 1995-929969	19950829
EP 778821	B1	19991020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10504836	T	19980512	JP 1995-508556	19950829
AT 185791	T	19991115	AT 1995-929969	19950829
US 5965741	A	19991012	US 1997-793023	19970221
PRIORITY APPL. INFO.:			GB 1994-17532	A 19940831
			WO 1995-GB2030	W 19950829

OTHER SOURCE(S): MARPAT 125:86305
 GI

L4 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The invention relates to compds. of formula D-X-A-O-CH(R3)-B-R' [I; A = (un)substituted ring system; B = (un)substituted 5- or 6-membered heteroaryl or Ph; D = (un)substituted ring system; X = (CHR4)n or (CHR4)pCR4:CR4(CHR4)q wherein n = 1-3 and p and q both = 0, or one of p and q = 1 and the other = 0; R1 = variety of substituents, positioned on ring B in either a 1,3 or 1,4 relationship with the OCH(R3) group for 6-membered rings, or in a 1,3 relationship for 5-membered rings; R3, R4 = H or Cl-4 alkyl] as well as their N-oxides, S-oxides, pharmaceutically acceptable salts, and in vivo-hydrolyzable esters and amides. The invention also relates to processes for preparation of I, intermediates

in their preparation, use of I as therapeutic agents, and pharmaceutical compns. containing them. For example, the representative compds. II and III were prepared. Benzenoid compound II was prepared via hydrolysis of its Me ester (88%), while tetrazole derivative III was prepared via cycloaddn. of HN3 with

the corresponding nitrile (78%). I are analgesics which may also (no data) possess antiinflammatory, antipyretic, and antidiarrheal properties.

In general, I had $pa2 > 5.3$ for inhibiting PGE2-induced contractions of isolated guinea pig ileum, and had oral ED50 of 0.01-100 mg/kg in the phenylbenzoquinone/AcOH induced writhing test in mice. No overt toxicity was seen in the writhing test at several multiples of the min. ED.


IT 178545-84-1P 178545-85-2
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity of effector, except adverse); BSU (Biological study, unclassified); SPN

L4 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of ortho-substituted arom. ethers as analgesics)


RN 178545-84-1 CAPLUS

CN Benzoic acid, 4-[[2-(2-phenylethyl)phenoxy]methyl]-2-hydroxy- (CA INDEX NAME)



RN 178545-85-2 CAPLUS

CN Benzoic acid, 4-[[2-bromo-6-(2-phenylethyl)phenoxy]methyl]-2-hydroxy- (CA INDEX NAME)



L4 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1991:42277 CAPLUS

DOCUMENT NUMBER: 114:42277

TITLE: Preparation of acetophenone derivatives as inflammation inhibitors
 Bollinger, Nancy G.; Goodson, Theodore, Jr.; Herron, David K.

PATENT ASSIGNEE(S): Eli Lilly and Co., USA

SOURCE: U.S., 22 pp. Cont.-in-part of U.S. Ser. No. 2,542, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4945099	A	19900731	US 1989-361873	19890605
US 5098613	A	19920324	US 1990-551221	19900711
US 5294613	A	19940315	US 1992-834181	19920207
			US 1987-2542	B2 19870112

PRIORITY APPLN. INFO.:


GB 1988-16433 19880711

US 1989-361873 A3 19890605

US 1990-551221 A1 19900711

OTHER SOURCE(S): CASREACT 114:42277; MARPAT 114:42277

GI




AB The title compds. I [R1 = H, R' O2C; Z = (CH2)n, phenylene; n = 1-8; G = CO; R2 = OH, halo, O(CH2)m; R3 = alkyl, alkanoyl, alkenyl, etc.; A = bond, alkylidene; R4 = cyano, (substituted) 5-tetrazolyl, etc.; R' = H, alkyl; m = 1-4; Y = H, cyano] were prepared. A mixture of resorcinol II (R5 = R6 = H), K2CO3, Br(CH2)4C.tplbond.N, and KI was heated at reflux overnight to give II [R5 = H, R6 = (CH2)4CN]. Compound 5-(4-acetyl-2-ethyl-5-hydroxyphenoxy)pentanenitrile at 50 mg/kg i.p. gave 26% inhibition of carrageenin-induced inflammation in rats.

IT 117705-58-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as inflammation inhibitor)


RN 117705-58-5 CAPLUS

L4 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Benzoic acid, 4-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]-2-hydroxy- (CA INDEX NAME)



103 - inflammation


X



L4 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1990:149114 CAPLUS
 DOCUMENT NUMBER: 112:149114
 TITLE: Recording materials containing electron-donating dye and salicylic acid derivatives
 INVENTOR(S): Iwakura, Ken; Sano, Masajiro
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
 CODEN: JQOQAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01168487	A	19890703	JP 1987-329268	19871225
US 4920091	A	19900424	US 1988-290669	19881227
PRIORITY APPLN. INFO.:			JP 1987-329268	A 19871225
			JP 1988-59919	A 19880314
			JP 1988-59920	A 19880314
			JP 1988-170546	A 19880708

GI




AB The title recording materials use electron-donating dye precursors and salicylic acid derivs. or their metal salts (as electron-acceptors) of the formula I (Z = bivalent groups; R = R1 = H, alkyl, Ph, alkoxy, halo). The materials show excellent developability and good image stability. Thus, a

L4 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1988:630544 CAPLUS
 DOCUMENT NUMBER: 109:230544
 TITLE: Leukotriene-inhibiting benzoyl- and alkanoylphenol derivatives for the treatment of inflammation, their pharmaceutical compositions, and processes for their preparation
 INVENTOR(S): Bollinger, Nancy Grace; Goodson, Theodore, Jr.; Herron, David Kent
 PATENT ASSIGNEE(S): Eli Lilly and Co., USA
 SOURCE: Eur. Pat. Appl., 55 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 276065	A1	19880727	EP 1988-300163	19880111
EP 276065	B1	19900606		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 1315279	C	19930330	CA 1987-555228	19871223
AU 8810164	A	19880714	AU 1988-10164	19880111
AU 601011	B2	19900830		
JP 6318644	A	19880804	JP 1988-3667	19880111
DK 8800104	A	19880919	DK 1988-104	19880111
HU 45960	A2	19880928	HU 1988-88	19880111
HU 200313	B	19900528		
CN 88100650	A	19881019	CN 1988-100650	19880111
ZA 8800154	A	19880927	ZA 1988-154	19880111
AT 53376	T	19900615	AT 1988-300163	19880111
ES 2036259	T3	19930516	ES 1988-300163	19880111
SU 1833372	A3	19930807	SU 1988-435086	19880111
PRIORITY APPLN. INFO.:			US 1987-2542	A 19870112
			EP 1988-300163	A 19880111

OTHER SOURCE(S): MARPAT 109:230544
 GI



AB The title derivs. [I; R1 = H, R'2C; Z = (CH2)n, C6H4; n = 1-8; R2 = OH, halo, O(CH2)mY; R3 = Cl-6 alkyl, Cl-6 alkanoyl, C2-4 alkenyl, Cl-4 alkoxy, Cl-3 hydroxyalkyl, CH2D; A = bond, Cl-10 alkylene; R4 = Cl-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, OH, cyano, halo, N3, NR5R6, COR7, S(O)pR8, 1,2,4-triazol-1-yl, 5-tetrazolyl optionally substituted by Cl-4 alkyl or (CH2)qCO2R', (un)substituted Ph; R' = H, Cl-4 alkyl; m, q = 1-4; Y = H, cyano; D = halo, Cl-4 alkoxy, SR8; R5, R6 = H, Cl-3 alkyl, C2-4 alkanoyl;



L4 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 color former sheet prep. by coating on a paper a dispersion of microcapsules contg. Crystal Violet lactone and a developer sheet prep. by coating a dispersion of II, a clay, CaCO3, ZnO, and Na hexametaphosphate in poly(vinyl alc.) and COOH-modified SBR latex were contacted with each other to give a high-quality recording sheet.
 IT 125941-04-0
 RL: USES (Uses)
 (electron acceptor, recording material containing, for developability and image stability)
 RN 125941-04-0 CAPLUS
 CN Zinc, [(3,3'-(1-methylethylidene)bis(4,1-phenyleneoxymethylene))bis(6-hydroxy-5-methylbenzoato)](2-)-O1,06)-(9CI) (CA INDEX NAME)



PAGE 1-A

PAGE 1-B

L4 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 NR5R6 = morpholino; R7 = OH, Cl-4 alkoxy, halo, NR5R6, NHOH; 5-tetrazolylamino, Cl-3 alkyl; R8 = Cl-4 alkyl; p = 0-2] are prep. as antiinflammatory agents. Me2CHCN was condensed with 4-(5-bromopentoxyl)-5-ethyl-2-hydroxyacetophenone in NH3(l) contg. NaNH2 to give I (R12 = Me, R2 = OH, R3 = Et, AR4 = (CH2)5CHMe2CN), which underwent cycloaddn. with Bu3SnN3, followed by methanolytic workup, to give ethylhydroxy[methyl(tetrazolyl)heptyloxy]acetophenone II. At 18 topically, II gave 60% inhibition of arachidonic acid-induced ear edema in mice. I also inhibited binding of LTB4 to peripheral human neutrophils by 96% at 10-6 M. Std. capsules contain a I compd. 250, starch 200, and Mg stearate 10 mg/capsule.
 IT 117705-58-5p
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as antiinflammatory)
 RN 117705-58-5 CAPLUS
 CN Benzoic acid, 4-[(4-acetyl-2-ethyl-5-hydroxyphenoxy)methyl]-2-hydroxy- (CA INDEX NAME)




L4 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1988:483606 CAPLUS
 DOCUMENT NUMBER: 109:83606
 TITLE: Thermal recording material containing dye-developer from salicylic acid or naphthoic acid derivatives and metal compound additive
 INVENTOR(S): Ikeda, Kensuke; Iwakura, Ken; Satomura, Masato
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 28 pp.
 CODEN: EPOXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 253666	A2	19880120	EP 1987-306308	19870716
EP 253666	A3	19880427		
R: DE, ES, FR, GB				
JP 63022683	A	19880130	JP 1986-167646	19860716
JP 06049392	B	19940629		
JP 63028691	A	19880206	JP 1986-173171	19860723
JP 63095977	A	19880426	JP 1986-243823	19861014
JP 63095978	A	19880426	JP 1986-243824	19861014
JP 63095979	A	19880426	JP 1986-243825	19861014
US 4918047	A	19900417	US 1989-294952	19890106
PRIORITY APPLN. INFO.:			JP 1986-167646	A 19860716
			JP 1986-173171	A 19860723
			JP 1986-243823	A 19861014
			JP 1986-243824	A 19861014
			JP 1986-243825	A 19861014
			US 1987-74119	B1 19870716


OTHER SOURCE(S): MARPAT 109:83606
 GI



AB In a thermal recording material comprising a colorless dye former and a developer, the developer contains a compound selected from I and II (R1 =

L4 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1985:5841 CAPLUS
 DOCUMENT NUMBER: 102:5841
 TITLE: Synthesis and properties of noncyclic polyether compounds. IX. New synthetic ionophores exhibiting selectivity for alkaline earth metal ions
 AUTHOR(S): Taguchi, Kazuhiro; Hiratani, Kazuhisa; Sugihara, Hideki; Ito, Kokoro
 CORPORATE SOURCE: Ind. Prod. Res. Inst., Higashi, 305, Japan
 SOURCE: Chemistry Letters (1984), (8), 1457-60
 CODEN: CMLTAG; ISSN: 0366-7022
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB New noncyclic polyethers (I; Z = polyoxyethylene, OCH2CH2CH2O; Z1 = CH2, OZ1 = OCH2CH2CH2O), which contain 3-carboxy-2-hydroxy-Ph group as one terminal group were prepared. These polyethers exhibit the ability to transport alkaline earth metal ions through chloroform liquid membrane, but not to transport alkali metal ions. Highly Ba++-selective ionophores were synthesized in this series.


IT 93580-19-9 93610-17-4 93610-19-6
 93610-20-9
 RL: RCT (Reactant); RACT (Reactant or reagent) (carrier, for transport of alkaline earth metal ions)
 RN 93580-19-9 CAPLUS
 CN Benzoic acid, 3-[[2-[2-[2-(2-carboxyphenoxy)ethoxy]ethoxy]ethoxy]-4(or 5)-(1,1-dimethylethyl)phenoxy]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

acyl, amino, aryloxymethyl, alkoxy, aryloxy; R2 = alkyl; X1 = H, alkyl, alkoxy, Ph, halogen; X2 = H, acyl, alkyl, alkoxy, halogen; M = H, metal with valency n; n = 1-3], and the recording layer contains a compd. of Zn, Mg, Ba, Ca, Al, Sn, Ti, Ni, Co, Mn, or Fe in the amt. of 0.05-10 mol/mol of the dye former. The recording material had high resistance toward chems. Thus, a recording material, prepd. by using crystal violet lactone, 4-β-phenoxyethoxysalicylic acid, ZnO, β-naphthyl benzyl ether (heat-fusible material), 1,1,3-tris(2-methyl-4-hydroxy-5-tert-butylphenyl)butane (discoloration inhibitor) and CaCO3, produced images stable at 40° and 90% relative humidity for 24 h.


IT 115720-17-7
 RL: USES (Uses)
 chemical (thermal recording material with developer from, with improved resistance)

RN 115720-17-7 CAPLUS
 CN Benzoic acid, 2-hydroxy-3,5-bis[(4-methylphenoxy)methyl]- (CA INDEX NAME)




R' - sub AKV
 R4 - me ✓

L4 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



2 (D1-Bu-t)


RN 93610-17-4 CAPLUS
 CN Benzoic acid, 3-[[2-[2-[2-(2-carboxyphenoxy)ethoxy]ethoxy]ethoxy]-4(or 5)-(1,1-dimethylethyl)phenoxy]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)



D1-Bu-t


RN 93610-19-6 CAPLUS
 CN Benzoic acid, 3-[[2-[2-[2-(2-carboxyphenoxy)ethoxy]ethoxy]-4(or 5)-(1,1-dimethylethyl)phenoxy]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



D1-Bu-t

RN 93610-20-9 CAPLUS
CN Benzoic acid, 3-[[2-[[2-(2-carboxyphenoxy)ethoxy]-4(or 5)-(1,1-dimethylethyl)phenoxy]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)]



D1-Bu-t